{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:58:36Z","timestamp":1790791116230,"version":"4.1.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Postoperative recurrence after hepatic resection for hepatocellular carcinoma (HCC) remains frequent. Readily available biomarkers that integrate host inflammatory, immune, and nutritional statuses may improve risk stratification. In this study, we evaluated the prognostic significance of the preoperative C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index in patients who underwent resection for primary HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, single-center study included 611 patients who underwent hepatic resection for primary HCC between 2004 and 2022. The CALLY index was defined as (albumin\u2009\u00d7\u2009lymphocytes)\/(CRP\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      ). Patients were classified into high (\u2265 2.2) and low (&lt; 2.2) CALLY index groups. Clinicopathological factors, disease-free survival (DFS), and overall survival (OS) were compared. Prognostic factors were assessed using Cox proportional hazards models, and propensity-score matching was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The low CALLY index group had lower albumin levels, higher CRP and alpha-fetoprotein levels, larger tumors, and more severe postoperative complications than the high CALLY index group. Patients with low CALLY index had significantly worse DFS and OS than those with high CALLY index. Multivariate analysis identified that the low CALLY index was independently associated with worse DFS (hazard ratio (HR), 1.86; 95% confidence interval (CI), 1.40\u20132.47; P\u2009&lt;\u20090.0001) and OS (HR, 1.93; 95% CI, 1.37\u20132.72; P\u2009=\u20090.0002). After propensity-score matching, the low CALLY index group continued to have significantly poorer DFS and OS rates than the high CALLY index group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The preoperative CALLY index was independently associated with DFS and OS after hepatic resection for primary HCC. This simple biomarker may help identify patients at a high risk of recurrence and poor survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358776","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:32:39Z","timestamp":1790789559000},"page":"e0358776","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the preoperative C-reactive protein-albumin-lymphocyte index and prognosis after hepatic resection for hepatocellular carcinoma"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-3586","authenticated-orcid":true,"given":"Tomonari","family":"Shimagaki","sequence":"first","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Harima","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakai","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Matono","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Konishi","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenkichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital","department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"3","key":"pone.0358776.ref001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"pone.0358776.ref002","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/bjs.10597","article-title":"Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma","volume":"104","author":"S Erridge","year":"2017","journal-title":"Br J Surg"},{"issue":"10415","key":"pone.0358776.ref003","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"S Qin","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"pone.0358776.ref004","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"M Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0358776.ref005","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00595-024-02930-x","article-title":"Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: A Japanese multicenter study","volume":"55","author":"N Iseda","year":"2025","journal-title":"Surg Today"},{"issue":"6","key":"pone.0358776.ref006","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"pone.0358776.ref007","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"L Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0358776.ref008","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"PJ Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0358776.ref009","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/cancers16122183","article-title":"Emerging prognostic markers in patients undergoing liver resection for hepatocellular carcinoma: A narrative review","volume":"16","author":"E Panettieri","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0358776.ref010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hpb.2021.06.414","article-title":"Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma","volume":"24","author":"H Iida","year":"2022","journal-title":"HPB (Oxford)"},{"issue":"3","key":"pone.0358776.ref011","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ags3.12637","article-title":"The impact of C-reactive protein-albumin-lymphocyte (CALLY) index on the prognosis of patients with distal cholangiocarcinoma following pancreaticoduodenectomy","volume":"7","author":"M Tsunematsu","year":"2022","journal-title":"Ann Gastroenterol Surg"},{"issue":"4","key":"pone.0358776.ref012","article-title":"Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy","volume":"13","author":"S She","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0358776.ref013","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-025-14074-3","article-title":"Integrating inflammation, nutrition, and immunity: the CALLY index as a prognostic tool in digestive system cancers - a systematic review and meta-analysis","volume":"25","author":"B Wu","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0358776.ref014","doi-asserted-by":"crossref","first-page":"100119","DOI":"10.1016\/j.soi.2024.100119","article-title":"Prognostic impact of the CALLY index in patients with resectable pancreatic cancer","volume":"2","author":"S Matsui","year":"2025","journal-title":"Surgical Oncology Insight"},{"issue":"8","key":"pone.0358776.ref015","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/hepr.14210","article-title":"The EZ-ALBI score as a prognostic tool for outcomes after resection of small hepatocellular carcinoma (<\/=3 cm","volume":"55","author":"T Shimagaki","year":"2025","journal-title":"). Hepatol Res"},{"issue":"1","key":"pone.0358776.ref016","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/s41598-025-03985-7","article-title":"The CRP-albumin-lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system","volume":"15","author":"H Zhao","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0358776.ref017","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ags3.12286","article-title":"Verification of inflammation-based prognostic marker as a prognostic indicator in hepatocellular carcinoma","volume":"3","author":"M Yamamoto","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"issue":"6","key":"pone.0358776.ref018","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ags3.12686","article-title":"Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma","volume":"7","author":"T Shimagaki","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"issue":"5","key":"pone.0358776.ref019","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/jgh.13250","article-title":"Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma","volume":"31","author":"A Hiraoka","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"pone.0358776.ref020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ags3.12804","article-title":"The prognostic impact of perioperative dynamic changes in cachexia index in patients with hepatocellular carcinoma","volume":"8","author":"M Akaoka","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"issue":"7","key":"pone.0358776.ref021","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00595-021-02427-x","article-title":"Clinical significance of preoperative inflammation-based score for the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy","volume":"52","author":"T Matsumoto","year":"2022","journal-title":"Surg Today"},{"issue":"10","key":"pone.0358776.ref022","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"D Seyhan","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"pone.0358776.ref023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12328-021-01394-7","article-title":"Intrahepatic recurrence of hepatocellular carcinoma after resection: an update","volume":"14","author":"M Tampaki","year":"2021","journal-title":"Clin J Gastroenterol"},{"issue":"10","key":"pone.0358776.ref024","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hpb.2017.06.002","article-title":"A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy","volume":"19","author":"S-L Yang","year":"2017","journal-title":"HPB (Oxford)"},{"issue":"4","key":"pone.0358776.ref025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00595-024-02924-9","article-title":"The C-reactive protein-albumin-lymphocyte (CALLY) index is a useful predictor of postoperative complications in patients with a colonic stent for obstructive colorectal cancer: A Japanese multicenter study","volume":"55","author":"T Shiraishi","year":"2025","journal-title":"Surg Today"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:32:44Z","timestamp":1790789564000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358776"}},"subtitle":[],"editor":[{"given":"Takehiko","family":"Hanaki","sequence":"first","affiliation":[{"name":"Tottori University Faculty of Medicine Graduate School of Medicine: Tottori Daigaku Igakubu Daigakuin Igakukei Kenkyuka","place":["JAPAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358776","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}